Portola Pharmaceuticals Inc. (PTLA) announced Thursday morning that there was no statistical difference in major bleeding between betrixaban and enoxaparin in its Phase 3 study. The study was intended to show the superiority of betrixaban over enoxaparin.
from RTT - Before the Bell http://ift.tt/1qaWl3N
via IFTTT
No comments:
Post a Comment